RVMD
Revolution Medicines, Inc. (RVMD) reported net income of -$1.13B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$1.13B | -88.5% |
| FY 2024 | -$600.00M | -37.6% |
| FY 2023 | -$436.00M | -75.1% |
| FY 2022 | -$249.00M | -33.2% |
| FY 2021 | -$187.00M | -72.9% |
| FY 2020 | -$108.16M | -126.9% |
| FY 2019 | -$47.66M | -14.1% |
| FY 2018 | -$41.79M | - |
Revolution Medicines, Inc. (RVMD) reported net income of -$1.13B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2025, Revolution Medicines, Inc.'s net income declined from -$41.79M to -$1.13B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.